Biodesix, Inc. (BDSX) – What Are Analysts Saying About This Stock?

Shares of Biodesix, Inc. (NASDAQ:BDSX) have received a consensus rating of “Moderate Buy” from the six research firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, four have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $36.25.

Several research analysts have recently weighed in on the stock. Canaccord Genuity Group boosted their price target on shares of Biodesix from $27.00 to $35.00 and gave the company a “buy” rating in a research report on Monday, August 10th. HC Wainwright restated a “buy” rating on shares of Biodesix in a research report on Thursday, October 22nd. Weiss Ratings raised shares of Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, September 8th. Finally, TD Cowen reaffirmed a “buy” rating and set a $40.00 target price (up from $30.00) on shares of Biodesix in a research note on Tuesday, October 13th.

Biodesix Stock Performance

Shares of Biodesix stock opened at $21.78 on Tuesday. The business’s 50 day moving average price is $26.36 and its 200 day moving average price is $18.71. The company has a market cap of $229.80 million, a price-to-earnings ratio of -6.87 and a beta of 0.56. The company has a debt-to-equity ratio of 5.12, a quick ratio of 2.85 and a current ratio of 2.85. Biodesix has a one year low of $5.26 and a one year high of $31.97.

Biodesix (NASDAQ:BDSX) last issued its earnings results on Wednesday, August 5th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.19. Biodesix had a negative return on equity of 788.19% and a negative net margin of 26.97%. The company had revenue of $26.86 million during the quarter, compared to analysts’ expectations of $26.03 million. On average, research analysts predict that Biodesix will post -2.68 EPS for the current year.

Insider Buying and Selling at Biodesix

In other news, Director Jack Schuler purchased 15,000 shares of the business’s stock in a transaction dated Wednesday, August 12th. The stock was acquired at an average price of $24.47 per share, for a total transaction of $367,050.00. Following the acquisition, the director directly owned 555,810 shares of the company’s stock, valued at approximately $13,600,670.70. This represents a 2.77% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders have purchased 42,600 shares of company stock valued at $1,033,062. Corporate insiders own 23.20% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Allworth Financial LP acquired a new stake in Biodesix during the second quarter worth $112,000. Walleye Capital LLC acquired a new position in shares of Biodesix in the 1st quarter valued at $157,000. Renaissance Technologies LLC purchased a new position in shares of Biodesix during the 1st quarter worth $173,000. Cetera Investment Advisers grew its holdings in shares of Biodesix by 20.0% during the 1st quarter. Cetera Investment Advisers now owns 12,000 shares of the company’s stock worth $174,000 after purchasing an additional 2,000 shares during the period. Finally, Squarepoint Ops LLC purchased a new position in shares of Biodesix during the 2nd quarter worth $354,000. 20.96% of the stock is currently owned by institutional investors and hedge funds.

About Biodesix

Biodesix, Inc is a data-driven diagnostic solutions company focused on improving the diagnosis and treatment of lung diseases, including lung cancer. The company combines proprietary molecular diagnostic technologies, clinical data, and artificial intelligence to help physicians assess disease risk and make more informed treatment decisions.

Its offerings include blood-based tests designed to help evaluate indeterminate pulmonary nodules, identify patients who may be at higher risk of lung cancer, and support treatment selection and monitoring.